Immunosuppresssion and Immune Escape in Liver Cancer

  • Qingqing Wang
  • Xuetao Cao

Abstract

Liver is regarded as a tolerogenic organ, and long-term persistence of hepatitis B and C viruses in the liver has been suggested to be partially due to the liver immunosuppressive or tolerogenic microenvironment. It is well known that hepatitis B and C viruses are associated with the development of hepatocellular carcinoma (HCC) in the later stages, and HCC cells develop many strategies to evade immunosurveillance or immunological attack. In this chapter we will summarize the recent advances in the identification and functional study of suppressive immune cells in liver microenvironment and investigate how they contribute to the HCC immunosuppressive microenvironment. Then we will introduce the development of effective approaches to induce immune responses to HCC.

Keywords

Natural Killer Cell Liver Cancer Major Histocompatibility Complex Class Treg Cell Immune Escape 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Wakabayashi M, Shiro T, Seki T, et al. Antigen expression in hepatocellular carcinoma. An immunohistochemical study. Cancer, 1995, 75: 2827–2835.PubMedCrossRefGoogle Scholar
  2. [2]
    Dong X Y, Yang X A, Wang Y D, et al. Zinc-finger protein ZNF165 is a novel cancer-testis antigen capable of eliciting antibody response in hepatocellular carcinoma patients. Br J Cancer, 2004, 91: 1566–1570.PubMedCrossRefGoogle Scholar
  3. [3]
    Yin Y H, Li Y Y, Qiao H, et al. TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. Br J Cancer, 2005, 93: 458–463.PubMedCrossRefGoogle Scholar
  4. [4]
    Li B, Wang Y, Chen J, et al. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587. Clin Exp Immunol, 2005, 140: 310–319.PubMedCrossRefGoogle Scholar
  5. [5]
    Ito H, Funahashi S, Yamauchi N, et al. Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target. Clin Cancer Res, 2006, 12: 3257–3264.PubMedCrossRefGoogle Scholar
  6. [6]
    Nishimura Y, Nakatsura T, Senju S. Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi, 2008, 31: 383–391.PubMedCrossRefGoogle Scholar
  7. [7]
    Stoop J N, van der Molen R G, Baan C C, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology, 2005, 41: 771–778.PubMedCrossRefGoogle Scholar
  8. [8]
    Unitt E, Rushbrook S M, Marshall A, et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology, 2005, 41: 722–730.PubMedCrossRefGoogle Scholar
  9. [9]
    Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res, 2007, 13: 902–911.PubMedCrossRefGoogle Scholar
  10. [10]
    Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology, 2007, 132: 2328–2339.PubMedCrossRefGoogle Scholar
  11. [11]
    Sancho D, Gomez M, Viedma F, et al. CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis. J Clin Invest, 2003, 112: 872–882.PubMedGoogle Scholar
  12. [12]
    Han Y, Guo Q, Zhang M, et al. CD69+ CD4+ CD25 T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol, 2009, 182: 111–120.PubMedCrossRefGoogle Scholar
  13. [13]
    Ilkovitch D, Lopez D M. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res, 2009, 69: 5514–5521.PubMedCrossRefGoogle Scholar
  14. [14]
    Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol, 2009, 182: 240–249.PubMedGoogle Scholar
  15. [15]
    Hoechst B, Ormandy L A, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+FOXP3+ T cells. Gastroenterology, 2008, 135: 234–243.PubMedCrossRefGoogle Scholar
  16. [16]
    Budhu A, Forgues M, Ye Q H, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell, 2006, 10: 99–111.PubMedCrossRefGoogle Scholar
  17. [17]
    Kuang D M, Wu Y, Chen N, et al. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood, 2007, 110: 587–595.PubMedCrossRefGoogle Scholar
  18. [18]
    Kuang D M, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med, 2009, 206: 1327–1337.PubMedCrossRefGoogle Scholar
  19. [19]
    Kuang D M, Peng C, Zhao Q, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology, 2010, 51: 154–164.PubMedCrossRefGoogle Scholar
  20. [20]
    You H, Ding W, Rountree C B. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology, 2010, 51: 1635–1644.PubMedCrossRefGoogle Scholar
  21. [21]
    Naugler W E, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science, 2007, 317: 121–124.PubMedCrossRefGoogle Scholar
  22. [22]
    Park E J, Lee J H, Yu G Y, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell, 2010, 140: 197–208.PubMedCrossRefGoogle Scholar

Copyright information

© Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Qingqing Wang
    • 1
  • Xuetao Cao
    • 2
  1. 1.Institute of ImmunologyZhejiang University School of MedicineHangzhouChina
  2. 2.National Key Laboratory of Medical Immunology & Institute of ImmunologySecond Military Medical UniversityShanghaiChina

Personalised recommendations